LianBio Stock

Equities

LIANY

US53000N1081

Biotechnology & Medical Research

Market Closed - OTC Markets 03:59:59 2024-05-10 pm EDT 5-day change 1st Jan Change
0.32 USD +6.24% Intraday chart for LianBio +1.88% -92.84%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2021 - Sales 2022 - Capitalization 178M
Net income 2021 -196M Net income 2022 -110M EV / Sales 2021 -
Net cash position 2021 378M Net cash position 2022 298M EV / Sales 2022 -
P/E ratio 2021
-1.08 x
P/E ratio 2022
-1.6 x
Employees 163
Yield 2021 *
-
Yield 2022
-
Free-Float 40.81%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.83%
1 week-4.11%
Current month-2.78%
1 month-2.84%
3 months-92.72%
6 months-92.67%
Current year-93.26%
More quotes
1 week
0.29
Extreme 0.2901
0.33
1 month
0.28
Extreme 0.28
0.35
Current year
0.24
Extreme 0.241
4.99
1 year
0.24
Extreme 0.241
4.99
3 years
0.24
Extreme 0.241
16.37
5 years
0.24
Extreme 0.241
16.37
10 years
0.24
Extreme 0.241
16.37
More quotes
Managers TitleAgeSince
Chief Executive Officer 44 19-09-30
Corporate Officer/Principal 42 20-03-31
General Counsel 56 20-01-31
Members of the board TitleAgeSince
Director/Board Member 51 20-07-31
Chief Executive Officer 44 19-09-30
Director/Board Member 58 22-04-06
More insiders
Date Price Change Volume
24-05-10 0.32 +6.24% 78 952
24-05-09 0.3012 -2.83% 90,074
24-05-08 0.31 -1.63% 263,256
24-05-07 0.3151 +0.08% 68,739
24-05-06 0.3148 +2.56% 86,096

Delayed Quote OTC Markets, May 09, 2024 at 01:45 pm EDT

More quotes
LianBio is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. It has a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications. Its product candidates include Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX-13 and LYR-210. Mavacamten is an oral small-molecule allosteric modulator of cardiac myosin, which is approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and is also being studied as a treatment for other diseases of diastolic dysfunction. TP-03 is a topical ophthalmic formulation of lotilaner, that is used for the treatment of demodex blepharitis (DB) and meibomian gland disease (MGD). NBTXR3 is a radio enhancer for the treatment of head and neck cancer and other solid tumors.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW